| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/09/2009 | WO2009043521A2 Use of urocortin iii and urocortin i as therapeutic agents |
| 04/09/2009 | WO2009043520A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | WO2009043519A2 Use of band 3 protein and pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043518A2 Use of a combination of cart peptides as a therapeutic agent |
| 04/09/2009 | WO2009043507A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043506A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043505A2 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer |
| 04/09/2009 | WO2009043504A2 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer |
| 04/09/2009 | WO2009043481A2 Use of adrenomedullin 13-52 and optionally retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043480A2 Use of leptin (22-56 ) as a therapeutic agent |
| 04/09/2009 | WO2009043479A2 Use of eaa-mart1 (26-35) for the treatment of human cytomegalovirus infections |
| 04/09/2009 | WO2009043478A2 Use of bubuc and optionally eaa-mart1 (26-35) as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043477A2 Use of glpl (7-36) alone or in combination with leptin 22-56 as a therapeutic agent |
| 04/09/2009 | WO2009043476A2 Neuromedin s as a therapeutic agent |
| 04/09/2009 | WO2009043469A2 Use of pneumadin as a therapeutic agent |
| 04/09/2009 | WO2009043468A2 Use of corticotropin-releasing factor as a therapeutic agent |
| 04/09/2009 | WO2009043467A1 U e of urocortin and corticotropin-releasing fact r as therapeutic agents |
| 04/09/2009 | WO2009043466A2 Therapeutic use of the peptide gluten exorphin a5 |
| 04/09/2009 | WO2009043465A2 Use of beta-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043464A2 Astressin and beta- endorphin for use as therapeutic agents |
| 04/09/2009 | WO2009043462A1 Use of neuropeptide af as a therapeutic agent |
| 04/09/2009 | WO2009043461A1 Use of a hnp-1 defensin peptide, alone or in combination with neuropeptide af, as a therapeutic agent |
| 04/09/2009 | WO2009043460A1 Use of alpha-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043459A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | WO2009043458A2 Use of oxytocin to treat many diseases |
| 04/09/2009 | WO2009043457A2 Use of human hemokinin-1 and optionally oxytocin to treat diseases involving excessive angiogenesis |
| 04/09/2009 | WO2009043456A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043455A2 Therapeutic uses of angiogenin 108-122 and gluten exorphin a5 |
| 04/09/2009 | WO2009043454A2 Use of pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043452A1 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent |
| 04/09/2009 | WO2009043451A2 Use of chorionic gonadotropin-beta (109-145) as a therapeutic agent |
| 04/09/2009 | WO2009043450A2 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents |
| 04/09/2009 | WO2009043449A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043448A2 Neuromedin u-25 and neuromedin s as therapeutic agents |
| 04/09/2009 | WO2009043447A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043441A1 D-ala-gln-octadecyl ester as a therapeutic agent |
| 04/09/2009 | WO2009043440A2 Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent |
| 04/09/2009 | WO2009043437A2 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections |
| 04/09/2009 | WO2009043436A2 Use of af12198 as a therapeutic agent |
| 04/09/2009 | WO2009043354A2 Combination treatment for the treatment of hepatitis c virus infection |
| 04/09/2009 | WO2009043136A1 Improving the energy status of an individual by enhanced usage of an endogenous fuel source |
| 04/09/2009 | WO2009024821A3 Oxadiazole derivatives as dgat inhibitors |
| 04/09/2009 | WO2009023416A3 Cosmetic methods and compositions for repairing human skin |
| 04/09/2009 | WO2009021868A3 Novel piperazine amide derivatives |
| 04/09/2009 | WO2008155666A3 Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases |
| 04/09/2009 | WO2008148710A3 Aryloxazole, aryloxadiazole and benzimidazole derivatives as modulators of somatostatins receptor activity |
| 04/09/2009 | WO2008122667A3 Ureylene derivatives |
| 04/09/2009 | WO2008121592A3 Acetyl coenzyme a carboxylase inhibitors |
| 04/09/2009 | WO2008063511A3 Methods for treating pompe disease |
| 04/09/2009 | WO2008023266A3 Kiwi extract |
| 04/09/2009 | US20090093639 Prodrugs of carbamate inhibitors of IMPDH |
| 04/09/2009 | US20090093527 [3-(2-{(3S)-3-[2-(Trifluoromethyl)phenoxy]pyrrolidin-1-yl}-1,3-thiazol-5-yl)-1,2,4-oxadiazol-5-yl]methanol, useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disorders, atherosclerosis, obesity, diabetes and fatty liver |
| 04/09/2009 | US20090093524 Compounds and methods for modulating fxr |
| 04/09/2009 | US20090093518 Piperidinyl-substituted isoquinolone derivatives |
| 04/09/2009 | US20090093516 Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| 04/09/2009 | US20090093511 Mast cell stabilizers in the treatment of obesity |
| 04/09/2009 | US20090093506 Copper antagonist compositions |
| 04/09/2009 | US20090093502 Improved lactate (leucine, arginine, methyl pyruvate, and methyl succinate) usage is accomplished through lactate precursors, adrenergic receptor agonists and insulinotropic agents |
| 04/09/2009 | US20090093499 Pharmaceutical composition |
| 04/09/2009 | US20090093489 Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
| 04/09/2009 | US20090093484 Novel compounds, their preparation and use |
| 04/09/2009 | US20090093478 N-aroyl cyclic amines |
| 04/09/2009 | US20090093475 Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals |
| 04/09/2009 | US20090093464 Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor |
| 04/09/2009 | US20090093457 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| 04/09/2009 | US20090093450 Agent for inhibiting visceral fat accumulation |
| 04/09/2009 | US20090093444 Cathepsin Cysteine Protease Inhibitors |
| 04/09/2009 | US20090093441 Preventing or reducing oxidative stress or oxidative cell injury |
| 04/09/2009 | US20090093433 SENSE mRNA THERAPY |
| 04/09/2009 | US20090093419 Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
| 04/09/2009 | US20090093413 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/09/2009 | US20090093412 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/09/2009 | US20090093402 Albumin Fusion Proteins |
| 04/09/2009 | US20090093397 Phaseolus vulgaris extracts, their use, and formulations containing them |
| 04/09/2009 | US20090092995 Method for Identifying Within a Mammal a DNA encoding a Physiologically Active Polypeptide |
| 04/09/2009 | US20090092727 Water-dispersible phytosterol-surfactant conglomerate particles |
| 04/09/2009 | US20090092695 Powdered health supplement having flavonoids absorbed onto the external surfaces of powder and which is suitable for lowering plasma glucose and plasma triglycerides, and which is produced from a mixture of dried grape skins, seeds and stems, treated with ethanol; diabetes treatment |
| 04/09/2009 | US20090092650 Sustained Delivery Formulations of Octreotide Compounds |
| 04/09/2009 | US20090092611 Antibodies that bind both bcma and taci |
| 04/09/2009 | US20090092605 Compositions and methods for the treatment of immune related diseases |
| 04/09/2009 | US20090092545 Antibodies that bind both bcma and taci |
| 04/09/2009 | DE4021517B4 Formulierungen mit verlangsamter Freisetzung wasserlöslicher Peptide Formulations with delayed release of water-soluble peptides |
| 04/09/2009 | CA2710406A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2701618A1 Pharmaceutical composition for inhibiting amyloid-beta protein accumulation |
| 04/09/2009 | CA2701612A1 Neuromedin u derivative |
| 04/09/2009 | CA2701406A1 Benzoxazinone derivative |
| 04/09/2009 | CA2701355A1 Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| 04/09/2009 | CA2701274A1 Lipopeptides for delivery of nucleic acids |
| 04/09/2009 | CA2701128A1 Antisense modulation of fibroblast growth factor receptor 4 expression |
| 04/09/2009 | CA2701120A1 Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof |
| 04/09/2009 | CA2701020A1 Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof |
| 04/09/2009 | CA2700963A1 Oxypiperidine derivatives and methods of use thereof |
| 04/09/2009 | CA2699264A1 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | CA2699260A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699255A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699114A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699113A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699109A1 Use of urocortin and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | CA2699107A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | CA2699105A1 Use of a peptide as a therapeutic agent |